- BioMerieux Increases FY Sales Forecast: Now expects organic sales growth between 8% to 10%, up from the previous forecast of 6% to 8%.
- First Half Results:
- Adjusted operating margin: 16.1%, down from 16.5% year-on-year.
- Adjusted operating income: €306 million, an increase of 5.2% year-on-year.
- Second Quarter Results:
- Sales: €936.7 million, an increase of 8.4% year-on-year. This surpassed the estimate of €889.8 million.
- Organic sales growth: 10.1%, significantly higher than the estimate of 6.55%.
- Comments:
- Full-year contributive operating income before non-recurring items is expected to grow organically by 12% to 17%.
- The full-year negative impact of exchange rates is expected to be around -€70 million, increased from the initial estimate of -€50 million.
- Analyst Ratings:
- 14 buy ratings
- 2 hold ratings
- 1 sell rating
A look at BioMerieux Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, BioMerieux shows a promising outlook for the long term. With favorable scores in Growth, Resilience, and Momentum, the company appears well-positioned to capitalize on opportunities and navigate challenges effectively. The Growth score indicates potential for expansion and development, while the Resilience score suggests the company’s ability to withstand market fluctuations. Additionally, the Momentum score highlights a positive trend that could drive further success for BioMerieux in the future.
BioMerieux, a company specializing in in vitro diagnostics for medical and industrial purposes, focuses on the diagnosis of infectious diseases and pathologies. In addition to its core medical applications, BioMerieux also plays a key role in analyzing food, pharmaceuticals, and environmental samples to assess their microbiological quality. With a balanced profile across Value, Dividend, Growth, Resilience, and Momentum, BioMerieux appears to have a solid foundation for sustainable growth and innovation in the diagnostics industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
